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Thimerosal is used as a preservative in Rabies vaccine. This study 
aimed at comparing potency and stability of inactivated animal rabies 
vaccine with and without thimerosal. Therefore, two groups of rabies 
vaccine were produced. The results indicated that thimerosal has no 
deleterious effect on the vaccine; furthermore, its elimination did not 
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     The first attempts to the production of 
Rabies vaccine occurred in the 1800s 
through a direct injecting of avirulent virus 
derived from animal sources. Nowadays, 
cell culture and recombinant techniques are 
mostly used for the production of the 
vaccine [1].  
By and large, most of vaccines need 
additives such as adjuvant, stabilizer and 
preservatives in their formulation process. 
Preservatives are added to prevent 
accidental microbial contamination. [2].  
Thimerosal, also called Thiomersal or 
Merthiolate, is an ethylmercury-containing 
pharmaceutical compound which has been 
used as a preservative or inactivating agent 
in some vaccines and other products since 
1930s. Due to its deleterious effect on live 
vaccines, it is used only in inactivated 
vaccines. While thimerosal has been taken 
out of childhood vaccines in the United 
States, its deleterious effect is in doubt. 
However, the problem with thimerosal is 
that it contains 49.6% mercury by weight, 
which may cause neurotoxicity in humans 
and animals [2-4]. 
Vaccine additives may affect the antigens 
and consequently influence the quality of 
the vaccine. They may affect vaccine 
quality assessment by impacting on the 
antigens (directly), and on the organism and 
its cells, subsequently on the immune 
response to the vaccine (indirectly). 
Since the compounds in the vaccine 
manufacturing process have a significant 
impact on vaccine quality, the potential 
impact of the used substances should be 
evaluated. Correspondingly, elimination and 
reduction of some materials such as 
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thimerosal from a product can have some 
unexpected effects on vaccine quality, 
safety and efficacy [5]. 
Although some studies have evaluated the 
safety and effectiveness of some 
preservatives in vaccines, there are few 
reports about thimerosal effect on the 
vaccine quality. 
In Iran, rabies is endemic and a major 
public health problem. Vaccination of 
animals has an important role in protecting 
animal health and public health against 
rabies. Rabies vaccine is produced for 
veterinary use in Iran and Thimerosal is 
used as a preservative in the vaccine. The 
study objective was to assess the effect of 
thimerosal on the vaccine potency, as well 
as its elimination effect, and ensuring the 
vaccine stability in these conditions. 
 
2. Methods 
     The study was carried out on Viral 
Vaccines Production Department, 
Production and Research Complex, Pasteur 
Institute of Iran and was approved by the 
Pasteur Institute’s ethics committee (No: 
94/0201/10267).  
The rabies virus strain PV- Paris was 
harvested according the manufacture 
process. Two groups of rabies vaccine were 
produced. One group was formulated with 
Thimerosal (Sigma, USA) and aluminum 
hydroxide (Alhydrogel ®) as adjuvant. 
Another group was formulated at the same 
time only with the adjuvant. 
 The immunogenic activity of rabies 
vaccine was evaluated by NIH method [1]. 
Briefly, at first, the median lethal dose 
(LD50) of CVS (Challenge virus standard) 
was determined in control mice and 
calculated according to the procedure of 
Reed and Muench. All mice under reference 
and test vaccine were immunized two times 
intraperitoneally with 0.5 ml of national 
reference and test vaccines in dilutions of 
1:5, 1:25, 1:125, 1:625 within an interval of 
7 days.  
Then, on day 14, all mice were challenged 
intracerebrally with CVS strain at a dose of 
30 LD50 of virus per 0.03 m1, and observed 
daily during 2 weeks for the development of 
rabies symptoms. The mice were observed 
for 14 days and the effective immunizing 
dose (ED50) of the reference and test 
vaccines were calculated based on the 
number of survivors and by Reed and 
Menche, which are expressed, relative to 
the reference vaccine in IU. 
Potency test was carried out at three interval 
time, at the beginning of the vaccines 
production, 6 and 10 months after.   
 Repeated measures ANOVA was 
performed for multiple comparisons 
between groups.  
 
3.A combined Results and 
Discussion section  
     Table 1 presents the potency of Rabies 
Vaccine between two study groups: vaccine 
with and without Thimerosal over ten 
months. The trend of the potency of Rabies 
vaccine between the two study groups over 
the time period was depicted as figure 1. At 
the first month, the potency of the vaccine 
with and without Thimerosal was 
approximately identical. Despite the fact 
that the potency was higher in the group of 
Thimerosal-free in comparing with the other 
one, there was no statistically significant 
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Table 1. Comparison of Relative potency of Thimerosal- containing and Thimerosal-free vaccines at months 1, 6 and 10 
(between and within group comparison) 
Total row (mean ± SD) Tenth month Sixth month First month  
1.50±0.07 1.56 1.49 1.43 Vaccine- without Thimerosal 
1.34±0.06 1.27 1.37 1.39 Vaccine- with Thimerosal 




Figure 1. Trend of potency of Rabies vaccine over ten months between two study groups (absence and presence of 
Thimerosal) 
 
Our results showed that there was no 
significant difference between Thimerosal- 
containing and Thimerosal-free vaccines at 
1, 6 and 10 months when held at 4°C 
(p=0.18). On the other hand, the time trend 
and multiple comparisons within each 
intervention group demonstrated that the 
potency of Rabies vaccine was not 
significantly affected over the time period 
(stability, p=0.97). 
There are differnt opinions on thimerosal 
and its effects: some studies have reported 
the harmful effects on organisms (human/ 
animals) and biological products. In 
addition to allergic reactions, several cases 
of mercury poisoning and autism have been 
reported from thimerosal- containing 
products. It seems that ethylmercury and 
inorganic Hg produced from Thimerosal 
metabolism accumulate in different organs 
such as brain [4, 6], while some studies did 
not demonstrate an association between 
thimerosal in vaccines and autism or 
neuropsychological effects [7, 8]. 
Beside thimerosal effects on man, it was 
revealed that it is toxic to cultured cells of 
human and animals. Thimerosal has shown 
to induce membrane and DNA damage and 
initiate apoptosis in neurons and fibroblasts 
[9]. 
The studies in animals detected toxicity 
effects of low doses of Thimerosal in 
vaccines [10]. The neurotoxic effects of 
thimerosal were also reported in developing 
rat brain, suggesting its involvement in 
neurodevelopmental disorders [11]. 
Kravchenko et al suggested that the toxic 
effect of thimerosal could damage cells at 
the injection site and induce the formation 
of autoantigens affecting the body [12]. 
However, Ni et al suggested that thimerosal 
significantly increases antibody response in 
a mouse model [13]. 
To evaluate the potency of Rabies vaccine, 
mice were injected with the vaccine; 
however the injection site, dose and effect 
duration should be considered in assessing 
the thimerosal effect [14, 15]. 
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Some studies indicated that the bacterial 
cultures devitalized with thimerosal had 
high antigenic values and found to incite 
antibody of higher titer than the heat killed 
vaccine [14]. 
On the other hand, another study indicated 
that Pertussis vaccine preserved with 
thimerosal was more toxic to mice than the 
unpreserved vaccine, and that increasing 
Thimerosal concentration increased the 
toxicity of the vaccine [16]. 
Among viral vaccines, thimerosal-free 
hepatitis B vaccine had similar 
seroprotection rates compared with 
thimerosal- containing vaccine [17]. This 
finding is similar to the present study’s 
results in that there was no significant 
difference between Rabies vaccines with 
and without Thimerosal. Since both vaccine 
potency and its stability were significant, 
the effect of thimerosal on Rabies vaccine 
potency under conditions of long term 
storage at + 4° was investigated. The study 
indicated that the stability of the vaccine 
was not affected by thimerosal, while 
studying for poliovirus vaccine indicated a 
different result. Sawyer et al. reported that 
the potency of enhanced inactivated 
poliovirus vaccine (eIPV) was significantly 
affected by the presence of thimerosal when 
held at 4°C for up to 8 months. Deleterious 
effect of thimerosal has been observed in 
eIPV, both with thimerosal, and in 
combination with diphtheria-tetanus-
pertussis (DTP) vaccine and thimerosal. 
Likewise, they reported that thimerosal 
enhanced sensitivity of poliovirus antigens 
to elevated temperature [18].  
Thimerosal had intermediate stability 
among different preservatives on 
Leishmania antigens, during 12 months of 
follow-up, while not showing long-term 
stability [19].  
Although a vaccine without an additive 
such as thimerosal or other unwanted 
materials would be more helpful without 
any safety issues for use in both human and 
animals and although nowadays rabies 
vaccines with and without thimerosal are 
produced in some countries, other studies 
seem necessary due to the different 
manufacturing process in each country. 
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